Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Dapagliflozin. Always confirm against the full prescribing information.
100 interactions
Acarbose
Dapagliflozin may increase the hypoglycemic activities of Acarbose.
Level 2 evidence
Acebutolol
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Acebutolol.
Level 1 evidence
Acetylsalicylic acid
The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Dapagliflozin.
Level 1 evidence
Alclometasone
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Dapagliflozin.
Level 1 evidence
Alogliptin
Dapagliflozin may increase the hypoglycemic activities of Alogliptin.
Level 2 evidence
Amcinonide
The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Dapagliflozin.
Level 1 evidence
Aminosalicylic acid
Aminosalicylic acid may increase the hypoglycemic activities of Dapagliflozin.
Level 2 evidence
Amiodarone
The risk or severity of hypoglycemia can be increased when Amiodarone is combined with Dapagliflozin.
Level 2 evidence
Amitriptyline
Amitriptyline may decrease the hypoglycemic activities of Dapagliflozin.
Level 2 evidence
Amlodipine
The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Dapagliflozin.
Level 2 evidence
Amobarbital
Amobarbital may increase the hypotensive activities of Dapagliflozin.
Level 2 evidence
Amoxapine
Amoxapine may decrease the hypoglycemic activities of Dapagliflozin.
Dapagliflozin has 418 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Dapagliflozin has 0 major, 295 moderate, and 123 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Dapagliflozin. Always confirm against the full prescribing information.